Related Experiment Videos
Current status of therapy with cefoxitin
Abstract:
Cefoxitin is a useful new chephamycin antibiotic available for IM of IV administration. It is a bactericidal beta-lactam antibiotic indicated for treatment of serious infections caused by a wide spectrum of gram-negative aerobic and anaerobic bacteria. Specific indications include: 1) polymicrobial infections (aerobic gram-negative rods and anaerobic bacteria); 2) nosocomial cephalothin-resistant gram-negative bacillary infections; 3) penicillin-resistant staphylococcal infections, and 4) anaerobic infections (pelvic, intraabdominal). Cefoxitin can be used as a single drug alternate to a two-drug antibiotic regimen (such as a cephalosporin-aminoglycoside combination) in polymicrobic infections of the pelvis, abdomen, skin, bones, or muscles. Cefoxitin is a significant drug in the armamentarium against anaerobic bacteria, particularly Bacteroides species. Since cefoxitin is highly resistant to staphylococcal beta-lactamase, it is effective against penicillin-resistant staphylococci. Cefoxitin has been effective in treating serious nosocomial infections caused by resistant aerobic gram-negative rods and anaerobic bacteria.
Insights
Cefoxitin, a potent beta-lactam antibiotic, effectively treats serious aerobic and anaerobic bacterial infections. It offers a single-drug alternative for complex infections, including those resistant to other antibiotics.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Cefoxitin is a novel cephamycin antibiotic administered via intramuscular or intravenous routes.
- It exhibits bactericidal activity against a broad spectrum of aerobic and anaerobic bacteria.
Purpose of the Study:
- To evaluate the efficacy of cefoxitin in treating serious bacterial infections.
- To highlight cefoxitin's role in managing infections caused by resistant pathogens.
Main Methods:
- Clinical data review of cefoxitin usage in various infection types.
- Assessment of cefoxitin's activity against specific bacterial strains, including resistant ones.
Main Results:
- Cefoxitin demonstrated effectiveness in treating polymicrobial, nosocomial, penicillin-resistant staphylococcal, and anaerobic infections.
- It proved particularly valuable against anaerobic bacteria like Bacteroides species.
- The antibiotic showed high resistance to staphylococcal beta-lactamase, ensuring efficacy against penicillin-resistant Staphylococcus.
Conclusions:
- Cefoxitin is a valuable therapeutic option for serious infections caused by a wide range of aerobic and anaerobic bacteria.
- Its ability to overcome resistance mechanisms makes it a significant agent in combating challenging infections.
- Cefoxitin can serve as a single-agent alternative to combination therapies in specific clinical scenarios.